Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder
Thickness of the cerebral cortex has been previously investigated for its potential as a biomarker in major depressive disorder (MDD). This is the first study to examine the longitudinal effects of a serotonin-norepinephrine reuptake inhibitor, desvenlafaxine succinate (DVS), on whole-brain cortical thickness (CT) in patients treated for MDD. We also aimed to replicate a previous finding of an association between improvement in clinical severity and CT in one of five predefined regions-of-interest (ROI). Twenty-five individuals with MDD received treatment with DVS (50 mg/day) for 8 weeks, with 19 completing the study. We...
Source: NeuroReport - March 4, 2019 Category: Neurology Tags: CLINICAL NEUROSCIENCE Source Type: research
Withdrawal-Emergent Dyskinesia Following Abrupt Discontinuation of Desvenlafaxine.
Authors: Wu L, Gerdts EA, Alam A
PMID: 30664338 [PubMed - in process] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - January 23, 2019 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine.
Authors: Garakani A
PMID: 30550646 [PubMed - in process] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - December 15, 2018 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.
CONCLUSION: Desvenlafaxine 20 to 50 mg/d was generally safe and well tolerated with no new safety signals identified in children and adolescents with MDD who received up to 6 months of treatment in these studies. Patients maintained the reduction in severity of depressive symptoms observed in all treatment groups at the end of the lead-in study.
PMID: 30419989 [PubMed - as supplied by publisher] (Source: CNS Spectrums)
Source: CNS Spectrums - November 13, 2018 Category: Neurology Authors: Atkinson S, Thurman L, Ramaker S, Buckley G, Jones SR, England R, Wajsbrot D Tags: CNS Spectr Source Type: research
Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing
Several companies offer pharmacogenetic testing for psychiatry on the basis of the claim that the outcome of drug selection is better when guided by such testing than when such testing is not used. This column examines the results of the GeneSight Psychotropic Test which groups various antidepressants and antipsychotics into 3 bins: green (“use as directed”), yellow (“use with caution”), and red (“use with increased caution and more frequent monitoring”). The authors examined how frequently the same drugs appeared in these different bins in 19 patients. They found that of the 22 antidepressants evaluated, 2 wer...
Source: Journal of Psychiatric Practice - November 1, 2018 Category: Psychiatry Tags: COLUMNS Source Type: research
Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
CONCLUSION: Milnacipran is a dual reuptake inhibitor of noradrenaline and serotonin, with greater effect on noradrenaline than serotonin, in contrast to the related drugs venlafaxine, desvenlafaxine and duloxetine. Rapidly absorbed irrespective of food, milnacipran has a half-life of approximately 8 hours, reaches steady state in 2 days and is excreted renally. Milnacipran helps a minority of patients with fibromyalgia by reducing pain and fatigue. It is also an effective antidepressant with efficacy comparable to venlafaxine and duloxetine, and a side effect profile characteristic of SNRIs. The dose range is 50-200 ...
Source: Australasian Psychiatry - September 10, 2018 Category: Psychiatry Authors: Keks NA, Hope J, Keogh S, Copolov DL Tags: Australas Psychiatry Source Type: research
Periodontal status in chronic periodontitis depressed patients on desvenlafaxine: An observational study
Conclusion: In our study, patients on desvenlafaxine were associated with less pocket depth and bleeding on probing. (Source: Journal of Indian Society of Periodontology)
Source: Journal of Indian Society of Periodontology - September 3, 2018 Category: Dentistry Authors: Anu Bhatia Rajinder Kumar Sharma Shikha Tewari Satish Chander Narula Hitesh Khurana Source Type: research
A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder
This study sought to assess feasibility and tolerability of using DESV in depressed patients on MMT. A total of 18 depressed individuals on MMT received DESV (50–100 mg/day) for 8 weeks. Participants were assessed for the following: (a) Safety of DESV using Systematic Assessment for Treatment Emergent Events-GI, ECG [corrected Q-T (QTc) interval measurement] and methadone serum levels; (b) depressive symptoms using Montgomery–Äsberg Depression Rating Scale (MADRS); and (c) other outcomes including anxiety, suicidality, craving, substance use, quality of life, and other depression scales. Registration number on Clini...
Source: International Clinical Psychopharmacology - July 31, 2018 Category: Psychiatry Tags: Original Articles Source Type: research
Switch to a manic episode after desvenlafaxine discontinuation in bipolar disorder.
PMID: 30079929 [PubMed - in process] (Source: Actas Espanolas de Psiquiatria)
Source: Actas Espanolas de Psiquiatria - July 1, 2018 Category: Psychiatry Authors: Muquebil Ali Al Shaban-Rodríguez OW, Álvarez de Morales E, Rodríguez-Turiel C, Fernández-Menéndez MA, García-Álvarez G Tags: Actas Esp Psiquiatr Source Type: research
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research
Journal of Child and Adolescent Psychopharmacology, Ahead of Print. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - April 5, 2018 Category: Pediatrics Authors: Jeffrey R. Strawn Paul E. Croarkin Source Type: research
Sexual Dysfunction in Patients with Antidepressant-treated Anxiety or Depressive Disorders: a Pragmatic Multivariable Longitudinal Study.
CONCLUSIONS: In patients with anxiety or depressive disorder, the risk of antidepressant-emergent sexual dysfunction at 6 weeks is low when drug doses are initially low with gradual up-titration. Baseline sexual dysfunction was independently associated with impaired sexual outcome. Men may be more likely than women to experience impaired sexual outcome. In patients with baseline sexual dysfunction, prescription of mirtazapine might be preferable to fluoxetine.
PMID: 29588433 [PubMed - in process] (Source: East Asian Archives of Psychiatry)
Source: East Asian Archives of Psychiatry - March 29, 2018 Category: Psychiatry Tags: East Asian Arch Psychiatry Source Type: research
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
CONCLUSIONS: The update did not change the major findings of the previous review. Based on low- to very low-quality evidence, the SNRIs duloxetine and milnacipran provided no clinically relevant benefit over placebo in the frequency of pain relief of 50% or greater, but for patient's global impression to be much or very much improved and in the frequency of pain relief of 30% or greater there was a clinically relevant benefit. The SNRIs duloxetine and milnacipran provided no clinically relevant benefit over placebo in improving health-related quality of life and in reducing fatigue. Duloxetine and milnacipran did not signi...
Source: Cochrane Database of Systematic Reviews - February 28, 2018 Category: General Medicine Authors: Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W Tags: Cochrane Database Syst Rev Source Type: research
Drug & ndash;drug interactions involving antidepressants: focus on desvenlafaxine
(Source: Neuropsychiatric Disease and Treatment)
Source: Neuropsychiatric Disease and Treatment - February 19, 2018 Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database
ConclusionSCCS shows promise for signal detection: it may highlight known associations for recent marketed products and has potential for early signal identification. SCCS performance varied by design choice and the nature of both exposure and event pair. Future work is needed to determine how effective the approach is in prospective testing and determining the performance characteristics of the approach. (Source: Drug Safety)
Source: Drug Safety - January 11, 2018 Category: Drugs & Pharmacology Source Type: research
Risk of hair loss with different antidepressants: a comparative retrospective cohort study
The aim of this study was to quantify the risk of hair loss with different antidepressants. A retrospective cohort study design using a large health claims database in the USA from 2006 to 2014 was utilized. A cohort of new user and mutually exclusive users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion were followed to the first diagnosis of alopecia. The cohort was comprised of 1 025 140 new users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion, wit...
Source: International Clinical Psychopharmacology - January 1, 2018 Category: Psychiatry Tags: Original Articles Source Type: research
